NMT1

Chr 17

N-myristoyltransferase 1

Also known as: HsNMT1, NMT

NCBI Gene: 4836UniProt: P30419

Myristate, a rare 14-carbon saturated fatty acid, is cotranslationally attached by an amide linkage to the N-terminal glycine residue of cellular and viral proteins with diverse functions. N-myristoyltransferase (NMT; EC 2.3.1.97) catalyzes the transfer of myristate from CoA to proteins. N-myristoylation appears to be irreversible and is required for full expression of the biologic activities of several N-myristoylated proteins, including the alpha subunit of the signal-transducing guanine nucleotide-binding protein (G protein) GO (GNAO1; MIM 139311) (Duronio et al., 1992 [PubMed 1570339]).[supplied by OMIM, Nov 2008]

0
Active trials
44
ClinVar variants
10
Pathogenic / LP
2.5
Missense Z
0.27
LOEUF· LoF intolerant
13
Pubs (2 yr)
Clinical Summary— NMT1
⚡
Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 1.00). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
10 Pathogenic / Likely Pathogenic· 33 VUS of 44 total submissions
Some data sources returned errors (1)

ensembl: TimeoutError: The operation was aborted due to timeout

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

gnomAD
LoF intolerant — likely haploinsufficient
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.27LOEUF
pLI 0.995
Z-score 4.49
OE 0.10 (0.05–0.27)
Highly constrained

Highly LoF-intolerant (top ~10% of genes)

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
2.48Z-score
OE missense 0.59 (0.52–0.67)
173 obs / 292.0 exp
Mild constraint

Moderately missense-constrained (top ~2.5%)

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.10 (0.05–0.27)
0≤0.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.59 (0.52–0.67)
0≤0.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.0.96
0≤1.21.6
LoF obs/exp: 3 / 29.2Missense obs/exp: 173 / 292.0Syn Z: 0.35

ClinVar Variant Classifications

44 submitted variants in ClinVar

ClinVar

Classification Summary

Pathogenic10
VUS33
Likely Benign1
10
Pathogenic
33
VUS
1
Likely Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
10
0
10
Likely Pathogenic
0
0
0
0
0
VUS
0
31
2
0
33
Likely Benign
0
0
0
1
1
Benign
0
0
0
0
0
Total03112144

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

NMT1 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

OMIM
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
Multiomics analysis identifies oxidative phosphorylation as a cancer vulnerability arising from myristoylation inhibition.
Beauchamp E et al.·J Transl Med
2024
Immunometabolism in the development of rheumatoid arthritis.
Weyand CM et al.·Immunol Rev
2020Review
Elucidating the role of N-myristoylation in the excessive membrane localization of PD-L1 in hypoxic cancers and developing a novel NMT1 inhibitor for combination with immune checkpoint blockade therapy.
Zhao H et al.·J Exp Clin Cancer Res
2025
Elevated co-expression of TIMM17A and NMT1 is associated with poor survival in non-small cell lung cancer.
Chan AA et al.·Sci Rep
2025
TNF-α-induced Inhibition of Protein Myristoylation Via Binding Between NMT1 and Sorbs2 in Osteoblasts.
Kutsuna S et al.·In Vivo
2024
MUC1 drives ferroptosis resistance in ICC via Src-mediated FSP1 deubiquitination and myristoylation.
Zhao Y et al.·Clin Transl Med
2025
DNA methylation biomarkers for cervical cancer risk prediction in HIV-positive Nigerian women.
Zheng Y et al.·Int J Cancer
2025
Targeting n-myristoyltransferases promotes a pan-Mammarenavirus inhibition through the degradation of the Z matrix protein.
Carnec X et al.·PLoS Pathog
2024
Targeting Src tyrosine kinase to enhance radioiodide uptake in breast cancer.
Poole VL et al.·Endocr Relat Cancer
2025
Cellular N-Myristoyl Transferases Are Required for Mammarenavirus Multiplication.
Witwit H et al.·Viruses
2024
Top 10 resultsSearch PubMed ↗
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Europe PMC
Top 5 resultsSearch Europe PMC ↗
Full-Text Mentions
NLP-detected gene mentions in article bodies · via PubTator3
PubTator3
N-myristoyltransferase 1-mediated Src Myristoylation Promotes Non-receptor Tyrosine Kinase Pathways in Oral Squamous Cell Carcinoma
Komiyama T et al.·In Vivo
2026
SPI1 Mediates N-Myristoyltransferase 1 to Advance Gastric Cancer Progression via PI3K/AKT/mTOR Pathway
Qiu P et al.·Can J Gastroenterol Hepatol
2023
Estimates of locus coeruleus function with functional magnetic resonance imaging are influenced by localization approaches and the use of multi-echo data
Turker HB et al.·Neuroimage
2021Functional
Mechanism of Ligand Discrimination by the NMT1 Riboswitch.
Kumar A et al.·J Chem Inf Model
2023Functional
Collateral metabolic vulnerabilities unveiled by loss of isozyme diversity in breast cancer
Ding R et al.·Genome Med
2025
NMT1 sustains ICAM-1 to modulate adhesion and migration of tumor cells.
Wang H et al.·Cell Signal
2023
NMT1 Enhances the Stemness of NSCLC Cells by Activating the PI3K/AKT Pathway.
Zou W et al.·Pharmacology
2022
N-Myristoylation by NMT1 Is POTEE-Dependent to Stimulate Liver Tumorigenesis via Differentially Regulating Ubiquitination of Targets
Zhu G et al.·Front Oncol
2021
Top 8 full-text resultsSearch PubTator3 ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →

External Resources

Links to major genomics databases and tools

Franklin by Genoox
AI-powered variant curation and clinical analysis
DECIPHER
Genomic variants and phenotypes in rare disease patients